These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10357966)

  • 1. Venous thromboembolic disease and combined oral contraceptives: A re-analysis of the MediPlus database.
    Todd J; Lawrenson R; Farmer RD; Williams TJ; Leydon GM
    Hum Reprod; 1999 Jun; 14(6):1500-5. PubMed ID: 10357966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.
    Jick H; Jick SS; Gurewich V; Myers MW; Vasilakis C
    Lancet; 1995 Dec; 346(8990):1589-93. PubMed ID: 7500750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
    Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Jun; 73(6):566-70. PubMed ID: 16730485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives.
    Farmer RD; Lawrenson RA; Todd JC; Williams TJ; MacRae KD; Tyrer F; Leydon GM
    Br J Clin Pharmacol; 2000 Jun; 49(6):580-90. PubMed ID: 10848722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral contraceptives and venous thromboembolic disease: the findings from database studies in the United Kingdom and Germany.
    Farmer RD; Lawrenson RA
    Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S78-86. PubMed ID: 9753314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Database and the UK Mediplus database.
    Farmer RD; Lawrenson RA; Todd JC; Williams TJ; MacRae K
    Hum Reprod Update; 1999; 5(6):688-706. PubMed ID: 10652979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women.
    Spitzer WO; Lewis MA; Heinemann LA; Thorogood M; MacRae KD
    BMJ; 1996 Jan; 312(7023):83-8. PubMed ID: 8555935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The differential risk of oral contraceptives: the impact of full exposure history.
    Lewis MA; MacRae KD; Kühl-Habichl D; Bruppacher R; Heinemann LA; Spitzer WO
    Hum Reprod; 1999 Jun; 14(6):1493-9. PubMed ID: 10359554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the risk of venous thromboembolism (VTE) among women taking third-generation oral contraceptives (OCs) in comparison with those taking contraceptives containing levonorgestrel?
    Meurer LN; Slawson JG
    J Fam Pract; 2001 Feb; 50(2):108. PubMed ID: 11219554
    [No Abstract]   [Full Text] [Related]  

  • 12. Combined oral contraceptives: venous thrombosis.
    de Bastos M; Stegeman BH; Rosendaal FR; Van Hylckama Vlieg A; Helmerhorst FM; Stijnen T; Dekkers OM
    Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010813. PubMed ID: 24590565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. The Transnational Research Group on Oral Contraceptives and the Health of Young Women.
    Lewis MA; Heinemann LA; MacRae KD; Bruppacher R; Spitzer WO
    Contraception; 1996 Jul; 54(1):5-13. PubMed ID: 8804801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical risk factors for venous thromboembolus in users of the combined oral contraceptive pill.
    Black C; Kaye JA; Jick H
    Br J Clin Pharmacol; 2002 Jun; 53(6):637-40. PubMed ID: 12047488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9.
    Lidegaard Ø; Nielsen LH; Skovlund CW; Skjeldestad FE; Løkkegaard E
    BMJ; 2011 Oct; 343():d6423. PubMed ID: 22027398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective multicentre study comparing levonorgestrel implants with a combined contraceptive pill: final results.
    Kirkman RJ; Bromham DR; O'Connor TP; Sahota JE
    Br J Fam Plann; 1999 Jul; 25(2):36-40. PubMed ID: 10454652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis.
    Jick H; Kaye JA; Vasilakis-Scaramozza C; Jick SS
    BMJ; 2000 Nov; 321(7270):1190-5. PubMed ID: 11073511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM; Algra A; Meijers JC; Bouma BN; Grobbee DE
    Thromb Haemost; 2002 Feb; 87(2):199-205. PubMed ID: 11859850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of age, body mass index, smoking and general health on the risk of venous thromboembolism in users of combined oral contraceptives.
    Nightingale AL; Lawrenson RA; Simpson EL; Williams TJ; MacRae KD; Farmer RD
    Eur J Contracept Reprod Health Care; 2000 Dec; 5(4):265-74. PubMed ID: 11245554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives.
    Schwingl PJ; Shelton J
    Contraception; 1997 Mar; 55(3):125-9. PubMed ID: 9114999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.